Regulatory Filings • Dec 20, 2021
Regulatory Filings
Open in ViewerOpens in native device viewer

This is an English translation of a Hebrew immediate report that was published on December 20, 2021 (Ref No.: 2021-01-182055) (hereafter: the "Hebrew Version"). This English version is only for convenience purposes. This is not an official translation and has no binding force. Whilst reasonable care and skill have been exercised in the preparation hereof, no translation can ever perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.
(the "Company")
To: To: www.isa.gov.il www.tase.co.il
December 20, 2021 Israel Securities Authority Tel Aviv Stock Exchange Ltd .
Dear Sirs and Madams,
The Company is honored to update its shareholders that on December 19, 2021, it succeeded in expressing cultivated Royal Jelly protein at the Company's laboratories. Royal Jelly protein, a component of pure bee-produced honey, has broad application for mankind in the food, medical and cosmetics industries1 . In addition, according to external sources, researches attribute pharmaceutical properties to this protein in human medicine, such as healing wounds, anti-bacterial and antifungal properties, decreasing cholesterol levels, lowering blood sugar levels, anti-cancerous properties, expansion of blood vessels, decreasing high blood pressure, and increasing the activity of the immune system2 . Therefore, the ability to express cultivated Royal Jelly protein, without any use of bees, is an additional significant milestone in the development of cultured honey and as a commodity.
According to the Company's estimation, the advantages of this technological development include:
1 https://dataintelo.com/report/royal-jelly-market/
2 https://www.nature.com/articles/s41467-018-05619-1
3 https://timesofindia.indiatimes.com/life-style/food-news/what-is-royal-jelly-and-why-it-isconsidered-a-superfood/photostory/84345638.cms?picid=84345718
4 https://www.fao.org/3/w0076e/w0076e16.htm

As extensively detailed in the outline of the Company's operations, as published in Appendix A of the Report on Convening a General Meeting dated May 20, 2021 (Ref. No.: 2021-01- 028399), the Company has developed an industrial process to produce cultivated honey, namely production of honey without bees. To realize this purpose, the Company must develop capabilities, among others, to create an artificial honey stomach which accurately simulates the activity of the bee's stomach using the biological processes of producing honey from nectar to obtain real honey.
The information mentioned in this notice is "Forward Looking Information" as defined in The Securities Law, 5728-1968, based on the information known to the Company as of this date, and on estimates and predictions which their realization depends, among others, on factors that are outside of the Company's control. To be noted, the Company is a research and development company and as such, its estimations might be realized in a different manner, if at all, given that the Company's research is preliminary and precedential.
Sincerely, OFIR DVASH, CEO BEEIO HONEY LTD
5 https://www.beeculture.com/royal-jelly-worker-bee-produced-protein-rich-mothers-milk/
6 See Footnote 3 above.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.